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Background. The insulin-like growth factor 1 receptor (IGF-1R) plays numerous crucial roles in cancer biology. The majority of
knowledge on IGF-1R signaling is concerned with its role in the activation of the canonical phosphatidyl inositol-3 kinase
(PI3K)/Akt and MAPK/ERK pathways. However, the role of IGF-1R ubiquitination in modulating IGF-1R function is an area of
current research. In light of this we sought to determine the relationship between IGF-1R phosphorylation, ubiquitination, and
modulation of growth signals. Methodology. Wild type and mutant constructs of IGF-1R were transfected into IGF-1R null
fibroblasts. IGF-1R autophosphorylation and ubiquitination were determined by immunoprecipitation and western blotting.
IGF-1R degradation and stability was determined by cyclohexamide-chase assay in combination with lysosome and
proteasome inhibitors. Principal Findings. IGF-1R autophosphorylation was found to be an absolute requirement for receptor
ubiquitination. Deletion of C-terminal domain had minimal effect on IGF-1 induced receptor autophosphorylation, however,
ubiquitination and ERK activation were completely abolished. Cells expressing kinase impaired IGF-1R, exhibited both receptor
ubiquitination and ERK phosphorylation, however failed to activate Akt. While IGF-1R mutants with impaired PI3K/Akt
signaling were degraded mainly by the proteasomes, the C-terminal truncated one was exclusively degraded through the
lysosomal pathway. Conclusions. Our data suggest important roles of ubiquitination in mediating IGF-1R signaling and
degradation. Ubiquitination of IGF-1R requires receptor tyrosine kinase activity, but is not involved in Akt activation. In
addition we show that the C-terminal domain of IGF-1R is a necessary requisite for ubiquitination and ERK phosphorylation as
well as for proteasomal degradation of the receptor.
Citation: Sehat B, Andersson S, Vasilcanu R, Girnita L, Larsson O (2007) Role of Ubiquitination in IGF-1 Receptor Signaling and Degradation. PLoS
ONE 2(4): e340. doi:10.1371/journal.pone.0000340
INTRODUCTION
In the past few years, the insulin-like growth factor 1 receptor
(IGF-1R) has emerged as a receptor tyrosine kinase (RTK) with
important roles in cancer biology. The physiological responses to
IGF-1R tyrosine kinase activation are diverse and include
differentiation, proliferation, protection from apoptosis, cellular
transformation, and cancer progression [1–3]
The IGF-1R is a tetrameric receptor tyrosine kinase consisting
of two ligand-binding extracellular a-subunits and two b-subunits
composing a transmembrane domain, an intracellular tyrosine
kinase domain and a C-terminal domain [4]. Ligand-receptor
interaction results in phosphorylation of tyrosine residues in the
tyrosine kinase (TK) domain (spanning from amino acid 973–
1229) of the b-subunit. The crystal structure of the inactive and
phosphorylated kinase domain has provided a molecular model of
the IGF-1R catalytic activity [5]. In unstimulated state, the
activation loop, containing the critical tyrosine (Y) residues 1131,
1135 and 1136, behaves as a pseudosubstrate that blocks the active
site. Upon ligand binding the three tyrosines of the activation loop
are transphosphorylated by the dimeric subunit partner. Phos-
phorylation of Y1135 and Y1131 destabilizes the auto-inhibitory
conformation of the activation loop, whereas phosphorylation of
Y1136 stabilizes the catalytically optimized conformation [5],
allowing substrate and ATP access. The phosphorylated tyrosine
residues serve as docking sites for other signaling molecules such as
insulin receptor substrate 1–4 (IRS-1-4) and Shc, leading to the
subsequent activation of the phosphatidyl inositol-3 kinase (PI3K),
the mitogen-activated protein kinase (MAPK), and the 14-3-3
pathways [1,4,6,7].
Recent data has shown that IGF-1R is a substrate for
ubiquitination, however, the role is unclear[8–11].Two E3 ligases,
Mdm2 [8] and Nedd 4 [9], have been demonstrated to be involved
in mediating the covalent attachment of ubiquitin moieties to
lysine residues in IGF-1R. In Mdm2-mediated ubiquitination, b-
arrestin function as a molecular scaffold in bridging the ligase to
the receptor [12]. Similarly, Nedd4-mediated IGF-1R ubiquitina-
tion requires Grb10 to function as an adapter protein [9].
However, in spite of identification of these ligases involved, the
understanding of the functional consequences and target residues
are still limited.
In general, activated receptors must be cleared from the cell
surface in order to desensitize the cell to mitogenic signals [13–15],
and numerous studies have suggested a role for ligand-induced
receptor internalization in the consequent degradation/desensiti-
zation of activated receptors [16]. There are several endocytic
pathways that can mediate internalization of cell surface receptors,
some of which are dependent on receptor ubiquitination [17,18].
The final step of receptor life cycle is degradation, which occurs
either in lysosomes or in proteasomes or in both. Degradation
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undergone ubiquitination, however ubiquitinated receptors can
also be degraded by lysosomes.
The fact that IGF-1R is ubiquitinated makes it as a possible
substrate for proteasomal degradation. However, several studies
have demonstrated that degradation of epidermal growth factor
receptor (EGFR), being the most investigated RTK in this respect,
is mediated by lysosomal proteases [13,19–21]. The pathway
through which IGF-1R is degraded is still an issue of debate.
Evidence for involvement of the proteasomal pathway are mainly
based on observations that the degradation of the IGF-1R can be
blocked by the proteasome inhibitor MG132 [9,22]. However, it
has recently been revealed that MG132 is not a specific inhibitor
of proteasomal proteases and may also block the lysosomal
pathway [23,24]. Accordingly, the degradation pathway respon-
sible for downregulation of IGF-1R is still unclear.
Using different mutated constructs we aimed to identify
functional sites and domains of IGF-1R necessary for receptor
ubiquitination and to address whether ubiquitination is involved in
control of signaling and degradation.
RESULTS
Functional sites and domains of IGF-1R
The b-subunit of the IGF-I receptor spans the membrane and
contains the TK domain, responsible for the overall kinase activity
of the receptor (Fig. 1A). The lysine K1003 serves as ATP-binding
site and an IGF-1R construct with a point mutation at this site
(K1003R) cannot be autophosphorylated [25]. The tyrosine
Y1136 is located in the activation loop and is important for
stabilization of kinase activity [5]. An IGF-1R construct with
a point mutation at this site (Y1136F) exhibits a decreased kinase
activity [26]. A phosphorylated Y950 is important for binding of
IRS-1 and Shc, and therefore is necessary for normal signaling
(Fig. 1A). Consequently, an IGF-1R construct with a single
mutation at Y950 site (Y950F) leads to impaired signaling [27].
The C-terminal domain is also involved in signaling [28,29]. A C-
tail truncated IGF-IR (D1245, missing the last 92 amino acids)
(Fig. 1A) exhibits impaired signaling [28,29], whereas the
Y950F+D1245 construct beside lacking the C-terminal domain
also has impaired IRS-1/Shc binding (Fig. 1A).
Figure 1. Wild type and mutant IGF-1R constructs. A. IGF-1R is a heterodimeric receptor with two identical ß-subunit and two identical a-subunits.
The a-subunit is completely extracellular, while the ß-subunit spans the membrane. The intracellular portion (residues 931–1337) has a TK domain
with intrinsic kinase activity. Important tyrosine residues in the TK domain, know as activation loop, are (Y1131, Y1135 and Y1136) shown in green.
Tyrosine residue Y950 (in blue) is, when phosphorylated, a docking site for binding of signaling molecules. Other important regions of the receptor
are the ATP binding site (K1003) and the C-terminal domain important for phosphorylation and signaling, respectively. B. The expression of all IGF-1R
variants were investigated on cells growing under basal conditions (complete medium supplemented with serum). Cell lysates were subjected to
western blotting using antibodies to IGF-1R (b-subunit) and GAPDH (loading control).
doi:10.1371/journal.pone.0000340.g001
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(IGF-1R knockout) stably transfected with wild type IGF-1R (here
referred to as wt), Y1136F, D1245 and Y950F+D1245 as well as
transiently transfected with K1003R. All constructs are of human
origin.
The expression level of the above IGF-1R variants under basal
conditions is demonstrated in Fig. 1B. As shown, D1245 and
Y950F+D1245 cells exhibit the strongest receptor expression.
Phosphorylation is necessary for ubiquitination of
IGF-1R
Upon ligand (IGF-1) stimulation the IGF-1R is rapidly autopho-
sphorylated and, as recently demonstrated, ubiquitinated [8,9].
However, the relationship between these two modifications has not
been studied in detail. To investigate this issue, wt IGF-1R and
K1003R cells were serum depleted for 24 h and then stimulated
with IGF-1 for the indicated times (Fig. 2). IGF-1R was
immunoprecipitated from cell lysates and analyzed by western
blotting for phosphotyrosine and ubiquitin modifications. Phos-
phorylation of wild type IGF-1R was detectable 1 min after ligand
exposure, peaking at 5 min but still detectable at later time points
(10 and 20 min) (Fig. 2A). The ubiquitination of the receptor
which starts simultaneously as phosphorylation, is visualized as
a high-molecular smear.90 kDa, peaking at 5 min (Fig 2A). The
graphs show the quantified signals of receptor phosphorylation
and ubiquitination based on 3 separate experiments. In the kinase
inactive IGF-1R cells (K1003R) where the receptor phosphoryla-
tion is abolished no ubiquitination was observed, indicating
that IGF-1R kinase activity is required for IGF-1-induced
ubiquitination.
C-terminal domain is required for IGF-1R
ubiquitination
Next we sought to investigate the potential requirement of specific
sites/domains of the IGF-1R for receptor ubiquitination. In this
respect, we used cells stably transfected with the 4 aforementioned
IGF-1R mutants (Fig. 1). As shown in Fig. 3, Y1136F cells (with
impaired IGF-1R kinase activity due to a point mutation at Y1136
site in the activation loop) is phosphorylated and ubiquitinated
shortly after ligand stimulation, however the phosphorylation and
ubiquitination patterns are transient when compared with wild
type (Fig. 2A). Both phosphorylation and ubiquitination of the
receptor were detectable exclusively after 1 min exposure to IGF-
1, however not after longer stimulation times (3–20 min). Cells
expressing Y950F receptors (with impaired signaling due to
reduced binding of Shc and IRS-1 to the receptor) displayed
phosphorylation and ubiquitination with similar kinetics as the
wild type IGF-1R (cf. Fig. 2A), although the ubiquitination signals
persisted longer in Y950F cells (Fig. 3). Interestingly, whereas the
C-tail truncated IGF-1Rs in D1245 and Y950F-D1245 cells are
fully phosphorylated (compared to the wild type receptor), the
ubiquitination capacity is completely abolished (Fig. 3). This
suggests that the C-terminal domain is critical for IGF-1 mediated
ubiquitination.
IGF-1R ubiquitination is important for ERK activation
Since we now have identified an IGF-1R construct with deficient
ubiquitination capacity we sought to investigate whether ubiqui-
tination influences the signaling responses mediated by IGF-1R.
We stimulated serum starved wt, K1003R, Y1136F and D1245
cells with IGF-1 for different time points (0–20 min). Phosphor-
Figure 2. Ubiquitination of IGF-1R is phosphorylation dependent. After 24-h serum starvation wt IGF-1R (A) and K1003R (B) cells were stimulated
for indicated time points with 50 ng/ml IGF-1. Lysates were immunoprecipitated (IP) with anti-IGF-1Rß (H60), and blotted with either anti-
phosphotyrosine (pY99) or anti-ubiquitin (p4D1). The graphs represent quantification (% of loading control) of three independent experiments.
Means and SDs are shown. Equal loading was confirmed by stripping and re-immunoblotting with anti-IGF-1Rß (C20).
doi:10.1371/journal.pone.0000340.g002
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and phosphorylation of Akt as a measure of PI3K activation. The
levels of expression of phospho-ERK1/2 and phospho-(S473) Akt
were investigated by immunoblot analysis (Fig. 4). Akt phosphor-
ylation induced by wild type IGF-1R was seen after 1 min of IGF-
1 stimulation, peaked at 3 min and was maintained until the final
time point. IGF-1 induced phosphorylation of ERK1/2 became
detectable at 3 min and reached a maximum at 10 min after
which the level declined (Fig. 4). As expected K1003R cells
showed neither Akt nor ERK phosphorylation. Consistent with
previous report [30] Y1136F transfected cells did not exhibit any
Akt activation, whereas ERK1/2 activation resembled that of wild
type IGF-1R (Fig. 4). Intriguingly, IGF-1 stimulation of C-
terminal truncated IGF-1R in D1245 cells activated Akt but not
ERKs. This suggests that IGF-1R ubiquitination, shown for wt
and Y1136F in Fig. 2 and 3, is important for signaling of the
MAPK pathway. Consequently, the transient ubiquitination
(detectable only at 1 min of ligand stimulation) observed for the
Figure 3. C-terminal domain is essential for ubiquitination of IGF-1R. After 24-h serum starvation Y1136, Y950F, D1245 and Y950F-D1245 cells were
stimulated for the indicated time points with IGF-1. Determinations of IGF-1R phosphorylation and ubiquitination were performed as described in
Fig. 2. The investigated signals from three independent experiments were quantified (% of loading control) and presented in graphs above each blot.
Means and SDs are shown.
doi:10.1371/journal.pone.0000340.g003
Figure 4. Ubiquitination of IGF-1R is crucial for ERK signaling. After 24 h serum starvation wt, Y1136F, K1003R, and D1245 cells were stimulated
with IGF-1 for the indicated times and lyzed. The lysates were resolved by SDS-PAGE and analyzed by western blotting with anti-phospho-Akt, anti-
phospho-ERK. The blots were then stripped and reprobed with anti-Akt, anti-Erk antibodies to demonstrate equal loading. The experiments were
repeated with similar results.
doi:10.1371/journal.pone.0000340.g004
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other hand, it is evident that activation of the PI3K/Akt signaling
pathway requires a higher IGF-1R kinase activity.
Ubiquitination status correlates with pathway of
IGF-1R degradation
We investigated degradation of the different IGF-1R constructs
using cyclohexamide (CHX) to block de novo protein synthesis as
described elsewhere [31–33]. Cells, grown under basal conditions,
were exposed to CHX for 6 or 12 h. To find out whether the
receptors were degraded by lysosomes and/or proteasomes,
lysosomal and proteasomal inhibitors were utilized. Cloroquine
is a lysosomotropic weak base, which diffuses across membranes in
a concentration-dependent manner. It rapidly becomes pro-
tonated thereby neutralizing the acidic environment of endocytic
vesicles [34]. Whereas, epoxomicin specifically targets the
proteasomes by inhibiting primarily the chymotrypsin-like activity
[24]. In contrast to peptide aldehyde proteasome inhibitors like
MG132, epoxomicin does not inhibit non-proteasomal proteases
such as trypsin, chymotrypsin, papain, calpain, and cathepsin B at
concentrations of up to 50 mM [24]. In addition, epoxomicin is
a more potent inhibitor of the chymotrypsin-like activity than
lactacystin and the peptide vinyl sulfone NLVS [24].
Wt, K1003R and D1245 cells were pre-treated with epoxomicin
or chloroquine before treatment with CHX and the levels of IGF-
1R expression were analyzed by western blotting (Fig. 5A) and
quantified by densitometry (Fig. 5B). As seen in Fig 5, in the
absence of inhibitor wild type IGF-1R was reduced by
approximately 50% after 12 h. The lysosome inhibitor (LyI)
completely prevented the degradation, while the proteasome
inhibitor (PI) had a moderate, although statistically significant
(P,0.05), stabilizing effect on IGF-1R. Fig. 5 also shows that the
ATPM receptor, being deficient in both ubiquitination and
phosphorylation, is not degraded at all during the 6 or 12 h
experiments. These data suggest that phosphorylation is necessary
for degradation and moreover indicate that the lysosomes
represent the main pathway by which the wild type IGF-1R is
degraded. Nevertheless, the fact that IGF-1R degradation is
somewhat delayed (approximately with 20%) in the presence of PI
(Fig. 5B) indicates that the proteasomal activity facilitates IGF-1R
degradation. We tried to address whether this effect is directly due
to involvement of proteasomes in IGF-1R degradation or is
mediated through other mechanisms. It has been suggested for
some receptors (e.g. interleukin 2 receptor and EGFR) that
ubiquitination is important for endosomal sorting where ubiquitin
seems to be required to prevent internalized receptors from
recycling by shunting them into a pathway that results in lysosomal
Figure 5. IGF-1R is degraded through both proteasomes and lysosomes. A. Wt, K1003R, and D1245 were either untreated (Unt) or pre-incubated
with epoxomicin (PI) or chloroquine (LyI) as described in Materials and methods. Cycloheximide (CHX) (50mg/ml) was added and the cells were further
incubated for 6 or 12 h. The cells were lyzed and subjected to SDS-PAGE and western blotting with antibody to IGF-1Rß. The proreceptor and 95 kDa
b-subunit of IGF-1R is indicated. B shows quantified data of IGF-1R, as normalized with GAPDH. Means and SDs of three separate experiments are
shown. * P,,0.05;* * P,,0.005.
doi:10.1371/journal.pone.0000340.g005
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pool of ubiquitin dramatically decreases after proteasome inhibitor
treatment leading to altered ubiquitination patterns of the receptor,
followed by altered internalization and lysosomal degradation.
Therefore,weinvestigated degradation ofIGF-1R inD1245 cells (C-
terminal truncated IGF-1R), which is phosphorylated but defective
in ubiquitination. The C-terminal truncated IGF-1R is entirely
protected from degradation by the lysosome inhibitor, whereas
proteasome inhibitor had no protecting effect on it (Fig. 5B). Taken
together, thissuggests that thedelay indegradation of wild type IGF-
1R caused by proteasome inhibition might be a direct effect of
receptor ubiquitination and not due to indirect effects suchas altered
internalization caused by lack of free ubiquitin
Unexpectedly, we observed that the mutant receptors in
Y1136F and Y950F cells, which both exhibited IGF-1R
ubiquitination (Fig. 3), are mainly degraded through proteasomes
(Fig. 6). Untreated Y1136F is degraded by 70% after 12 h.
Lysosome inhibitor decreased this degradation by 40% while the
proteasome inhibitor abolished it totally. The same pattern was
seen in Y950F cells. In Y950F-D1245 cells, with truncated C-tail
and impaired IRS-1/Shc binding, the receptor showed essentially
similar responses as in D1245 cells (Fig. 5 and 6).
DISCUSSION
In this study we sought to shed light on regulation of and role of
IGF-1R ubiquitination. The results presented here show that
phosphorylation of the receptor is necessary for its ubiquitination.
Furthermore, we can state that the C-terminal domain of the
receptor is needed in this context. In wild type IGF-1R the profile
of ubiquitination matches its phosphorylation status. However, C-
tail truncated IGF-1R cannot be ubiquitinated in spite of its
normal kinase activity. Since, C-terminal truncation of IGF-1R
inhibits receptor ubiquitination, one could speculate that the
lysine(s) required for ubiquitination are located in the C-tail.
However, out of the 29 lysine residues in the b-subunit of the IGF-
1R only three are in the C-tail domain. Although these three
lysines might function as ubiquitin acceptors, another possibility is
that the C-terminal domain functions as an E3 ligase binding site.
Further studies are, however, required to understand the distinct
mechanism by which C-terminal truncation inhibits ubiquitination
of IGF-1R. Importantly, when ubiquitination of IGF-1R is
prevented by C-tail truncation the receptor is degraded explicitly
through the lysosomes, suggesting a role of IGF-1 induced
ubiquitination in proteasomal degradation of the receptor.
Intriguingly, we observed that the IGF-1R mutant Y1136F is
mainly degraded via the proteasomes. Since this mutant did not
exhibit any Akt phosphorylation, but intact phosphorylation of
ERK1/2, it is possible that the PI3K/Akt pathway has a positive
regulatory influence on lysosomal degradation. A similar pre-
dominance of proteasomal degradation occurred in case of the
Y950F mutant, which has an impaired IRS-1 binding [38,39].
Further support for a role of the PI3K/Akt signaling pathway in
this context is contributed by our observations that all IGF-1R
constructs exhibiting fully detectable Akt phosphorylation are
mainly degraded by the lysosomes. Interestingly, accumulating
Figure 6. Intact Y1136 and Y950 are important for lysosomal degradation of IGF-1R. Y1136F, Y959F, and Y950F-D1245 cells were pre-incubated
without or with PI or LyI and treated with CHX as described in Fig. 5. After western blotting quantification of IGF-1R, as normalized with GAPDH, was
performed. Means and SDs of three different experiments are shown. *P,,0.05;* *P,,0.005.
doi:10.1371/journal.pone.0000340.g006
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phorylation and nuclear localization of Mdm2 [40–42]. These
results could offer an explanation regarding the different pattern of
IGF-1R degradation in the various mutants. Consistently, in
mutant cell lines with impaired Akt activation (Y950F and
Y1136F), Mdm2 is probably not phosphorylated with an increased
cytoplasmic pool of Mdm2 as a consequence. Since Mdm2 is
a ligase required for ubiquitination of IGF-1R [8], the raised levels
of cytoplasmic Mdm2 would increase ubiquitination of IGF-1R
followed by proteasomal degradation.
In summery we have identified a receptor domain critical for
the IGF-1R ubiquitination and show that this post-modification is
dependant of phosphorylation of the receptor. Furthermore, we
show the co-existence of both proteasomal and lysosomal pathway
for IGF-1R degradation, in which PI3K/Akt signaling may be
important for the lysosomal pathway and ubiquitination for the
proteasomal one. Also, IGF-1R activated MAPK/ERK signaling
may be controlled by ubiquitination of the receptor.
MATERIALS AND METHODS
Reagents
Polyclonal IGF-1R antibodies (C-20, and H-60), monoclonal
antibody to phosphotyrosine (PY99) and monoclonal antibody to
ubiquitin (p4D1) were purchased from Santa Cruz Biotechnology
Inc., Santa Cruz, CA. Anti-pErk1/2, anti-Erk1/2, anti-pAkt (serin
473), and anti-Akt antibodies were purchased from Cell Signaling
Technology, Danvers, MA. Protein G Sepharose from Amersham
Pharmacia Biotech (Uppsala, Sweden). All other reagents unless
stated otherwise were from Sigma (St Louis, MO, USA).
Cell cultures
Cell lines used are derived from 3T3-like fibroblasts isolated from
mouse embryos with a targeted disruption of the IGF-IR gene (R-
cells) [43]. The cells R- cells were stably transfected with human
wild type IGF-1R or mutated variants of human IGF-1R (Y950F,
D1245, Y950F-D1245 and Y1136). These cell lines were kind gifts
from Dr. Renato Baserga (Thomas Jefferson University, Philadel-
phia, PA). R- cells were transiently transfected with a plasmid
containing IGF-1R with mutation at the ATP binding site
(K1003R). This plasmid was provided by R Baserga. Cells
transfected with wild type IGF-1R and K1003R were maintained
in Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 10% (v/v) fetal calf serum, 10 mM L-Glu, 5 mg/ml
penicillin/streptomycin and G418 (Promega). Cells transfected
with Y950F-D1245, Y950F and Y1136F were routinely cultured in
DMEM supplemented with 10% fetal bovine serum (FBS) 10 mM
L-Glu, 5 mg/ml penicillin/streptomycin and hygromycin
(250 mg/ml). Cells transfected with Y950F were routinely cultured
in DMEM supplement with 10% FBS, 10 mM L-Glu, 5 mg/ml
penicillin/streptomycin and puromycin (2 mg/ml).
Transient transfection
R- cells were seeded to 90% confluence in 10-cm dishes (Falcon)
with plasmids using Lipofectamine 2000 (Life Technologies, Inc.,
Grand Island, NY), according to the manufacturer’s instructions.
24 h after transfection cells were splited into 6 well plates and
cultured for an additional 24 h in the presence of 0.6 mg/ml
G418. During the last 24 h, cells were starved and then stimulated
for indicated times with 50 ng/ml IGF-1. Cells were lyzed in lysis
buffer (0.5% Triton-x-100, 0.5% Doc Deoxycholic acid,150 mM
NaCl, 20 mM Tris pH 7.5, 10 mM EDTA, 30 mM sodium
pyrophosphate, 10% glycerol, 1 mM phenylmethylsulfonyl fluo-
ride, protease inhibitor cocktail tablet (Roche, Mannheim,
Germany), phosphatase inhibitor 1 and 2, and 10 mM N-
Ethylmaleimide). Protein extracts were prepared for immunopre-
cipitation or western blot analyses.
SDS/PAGE and western blot analysis
Cell lysate were distracted as described above. Protein samples
were dissolved in a sample buffer containing 0.0625 M Tris?HCl
(pH 6.8), 20% glycerol, 2% SDS, bromophenol blue, and 2b-
mercaptoetanol. Samples corresponding to 50–100 mg of cell
protein were separated by 7.5% or 4–12% gradient sodium
dodecyl sulphate polyacrylamide gel electrophoresis (SDS PAGE).
Molecular weight markers (Bio-Rad) were run simultaneously.
After SDS/PAGE the proteins were transferred onto nitrocellulose
membranes (Hybond, Amersham, UK) and blotted with the
indicated antibodies. This was followed by washes and incubation
with a HRP conjugated secondary antibody (ImmunoPure anti-
body, Pierce), and detected with (Hyperfilm-ECL, Amersham,
UK).
Immunoprecipitation
Cells were cultured to subconfluency in 6-cm plates. The cells
were serum-depleted for 24 h, and then stimulated by IGF-1
(50 ng/ml) at indicated time points. For determination of IGF-1R
phosphorylation and ubiquitination, cell lysates were extracted
with lysis buffer as described above. Twenty ml of protein G
Sepharose and 1 mg of antibody were added to 1 mg of protein
material. After overnight incubation at 4uC on a rocker platform,
the immunoprecipitates were collected by centrifugation in
a microcentrifuge at 2,500 rpm for 2 min. The supernatant was
discarded, whereupon the pellet was washed 2 times with lysis
buffer and 1 time with PBS and then dissolved in a sample buffer
for SDS/PAGE and further was analyzed by western blotting.
Degradation assay
Protein degradation was assessed by cycloheximide-chase assay as
to previously described [31,32]. The effect of lysosome inhibitor
(LyI), cloroquine and proteasome inhibitor (PI), epoxomicin on the
stability of the entire IGF-1R pool was examined by immunoblot
analysis at 6- and 12 h after treatment with cycloheximide. Cell
lines with wild type and different IGF-1R mutants were grown on
plates and the levels of IGF-1R were studied with and without PI
and LyI. The experiment was preformed in complete culture
medium in order to follow receptor downregulation under
physiological conditions. The protein synthesis of the cells was
subsequently inhibited with cycloheximide (CHX, 50 mg/ml) that
was maintained during the whole experiment. In cases where
proteasomes were inhibited, epoxomicin was added to a final
concentration of 100 nM, 6 h [24,44] prior to addition of
cycloheximide. Lysosomes were inhibited by adding chloroquine
to a final concentration of 50 mM 30 min [45,46] before addition
of cycloheximide and were present throughout the experiment.
ACKNOWLEDGMENTS
Author Contributions
Conceived and designed the experiments: OL BS. Performed the
experiments: RV BS SA. Analyzed the data: OL RV BS SA LG.
Contributed reagents/materials/analysis tools: OL LG. Wrote the paper:
OL BS.
IGF-1R Ubiquitination
PLoS ONE | www.plosone.org 7 April 2007 | Issue 4 | e340REFERENCES
1. Baserga R (1999) The IGF-I receptor in cancer research. Exp Cell Res 253: 1–6.
2. Larsson O, Girnita A, Girnita L (2005) Role of insulin-like growth factor 1
receptor signalling in cancer. Br J Cancer 92: 2097–2101.
3. Girnita A, Girnita L, del Prete F, Bartolazzi A, Larsson O, et al. (2004)
Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and
malignant cell growth. Cancer Res 64: 236–242.
4. LeRoith D, Werner H, Neuenschwander S, Kalebic T, Helman LJ (1995) The
role of the insulin-like growth factor-I receptor in cancer. Ann N Y Acad Sci
766: 402–408.
5. Favelyukis S, Till JH, Hubbard SR, Miller WT (2001) Structure and
autoregulation of the insulin-like growth factor 1 receptor kinase. Nat Struct
Biol 8: 1058–1063.
6. Baserga R (2000) Insulin-like growth factor I receptor signalling in prostate
cancer cells. Growth Horm IGF Res 10 Suppl A: S43–44.
7. Yu H, Rohan T (2000) Role of the insulin-like growth factor family in cancer
development and progression. J Natl Cancer Inst 92: 1472–1489.
8. Girnita L, Girnita A, Larsson O (2003) Mdm2-dependent ubiquitination and
degradation of the insulin-like growth factor 1 receptor. Proc Natl Acad Sci U S A
100: 8247–8252.
9. Vecchione A, Marchese A, Henry P, Rotin D, Morrione A (2003) The Grb10/
Nedd4 complex regulates ligand-induced ubiquitination and stability of the
insulin-like growth factor I receptor. Mol Cell Biol 23: 3363–3372.
10. Girnita L, Girnita A, Brodin B, Xie Y, Nilsson G, et al. (2000) Increased
expression of insulin-like growth factor I receptor in malignant cells expressing
aberrant p53: functional impact. Cancer Res 60: 5278–5283.
11. Girnita L, Shenoy SK, Sehat B, Vasilcanu R, Vasilcanu D, et al. (2007) beta -
arrestin and Mdm2 mediate IGF-1 receptor stimulated ERK activation and cell
cycle progression. J Biol Chem doi:10.1074/jbc.M611526200.
12. Girnita L, Shenoy SK, Sehat B, Vasilcanu R, Girnita A, et al. (2005) {beta}-
Arrestin is crucial for ubiquitination and down-regulation of the insulin-like
growth factor-1 receptor by acting as adaptor for the MDM2 E3 ligase. J Biol
Chem 280: 24412–24419.
13. Alexander A (1998) Endocytosis and intracellular sorting of receptor tyrosine
kinases. Front Biosci 3: d729–738.
14. Jackson PK, Eldridge AG, Freed E, Furstenthal L, Hsu JY, et al. (2000) The lore
of the RINGs: substrate recognition and catalysis by ubiquitin ligases. Trends
Cell Biol 10: 429–439.
15. Wells A, Welsh JB, Lazar CS, Wiley HS, Gill GN, et al. (1990) Ligand-induced
transformation by a noninternalizing epidermal growth factor receptor. Science
247: 962–964.
16. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat
Rev Mol Cell Biol 2: 127–137.
17. Di Guglielmo GM, Le Roy C, Goodfellow AF, Wrana JL (2003) Distinct
endocytic pathways regulate TGF-beta receptor signalling and turnover. Nat
Cell Biol 5: 410–421.
18. Sigismund S, Woelk T, Puri C, Maspero E, Tacchetti C, et al. (2005) Clathrin-
independent endocytosis of ubiquitinated cargos. Proc Natl Acad Sci U S A 102:
2760–2765.
19. Authier F, Metioui M, Bell AW, Mort JS (1999) Negative regulation of
epidermal growth factor signaling by selective proteolytic mechanisms in the
endosome mediated by cathepsin B. J Biol Chem 274: 33723–33731.
20. Haglund K, Sigismund S, Polo S, Szymkiewicz I, Di Fiore PP, et al. (2003)
Multiple monoubiquitination of RTKs is sufficient for their endocytosis and
degradation. Nat Cell Biol 5: 461–466.
21. Herbst JJ, Opresko LK, Walsh BJ, Lauffenburger DA, Wiley HS (1994)
Regulation of postendocytic trafficking of the epidermal growth factor receptor
through endosomal retention. J Biol Chem 269: 12865–12873.
22. Park DS, Cohen AW, Frank PG, Razani B, Lee H, et al. (2003) Caveolin-1 null
(2/2) mice show dramatic reductions in life span. Biochemistry 42:
15124–15131.
23. Alwan HA, van Zoelen EJ, van Leeuwen JE (2003) Ligand-induced lysosomal
epidermal growth factor receptor (EGFR) degradation is preceded by
proteasome-dependent EGFR de-ubiquitination. J Biol Chem 278:
35781–35790.
24. Meng L, Mohan R, Kwok BH, Elofsson M, Sin N, et al. (1999) Epoxomicin,
a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory
activity. Proc Natl Acad Sci U S A 96: 10403–10408.
25. Sperandio S, Poksay K, de Belle I, Lafuente MJ, Liu B, et al. (2004) Paraptosis:
mediation by MAP kinases and inhibition by AIP-1/Alix. Cell Death Differ 11:
1066–1075.
26. Li S, Ferber A, Miura M, Baserga R (1994) Mitogenicity and transforming
activity of the insulin-like growth factor-I receptor with mutations in the tyrosine
kinase domain. J Biol Chem 269: 32558–32564.
27. Yu D, Watanabe H, Shibuya H, Miura M (2003) Redundancy of radioresistant
signaling pathways originating from insulin-like growth factor I receptor. J Biol
Chem 278: 6702–6709.
28. Chow JC, Condorelli G, Smith RJ (1998) Insulin-like growth factor-I receptor
internalization regulates signaling via the Shc/mitogen-activated protein kinase
pathway, but not the insulin receptor substrate-1 pathway. J Biol Chem 273:
4672–4680.
29. Furlanetto RW, Dey BR, Lopaczynski W, Nissley SP (1997) 14-3-3 proteins
interact with the insulin-like growth factor receptor but not the insulin receptor.
Biochem J 327( Pt 3): 765–771.
30. Vasilcanu D, Girnita A, Girnita L, Vasilcanu R, Axelson M, et al. (2004) The
cyclolignan PPP induces activation loop-specific inhibition of tyrosine phos-
phorylation of the insulin-like growth factor-1 receptor. Link to the phosphatidyl
inositol-3 kinase/Akt apoptotic pathway. Oncogene 23: 7854–7862.
31. Gardner R, Cronin S, Leader B, Rine J, Hampton R (1998) Sequence
determinants for regulated degradation of yeast 3-hydroxy-3-methylglutaryl-
CoA reductase, an integral endoplasmic reticulum membrane protein. Mol Biol
Cell 9: 2611–2626.
32. Gardner RG, Hampton RY (1999) A ‘distributed degron’ allows regulated entry
into the ER degradation pathway. Embo J 18: 5994–6004.
33. Zaiss DM, Standera S, Kloetzel PM, Sijts AJ (2002) PI31 is a modulator of
proteasome formation and antigen processing. Proc Natl Acad Sci U S A 99:
14344–14349.
34. de Duve C, de Barsy T, Poole B, Trouet A, Tulkens P, et al. (1974)
Commentary. Lysosomotropic agents. Biochem Pharmacol 23: 2495–2531.
35. Rocca A, Lamaze C, Subtil A, Dautry-Varsat A (2001) Involvement of the
ubiquitin/proteasome system in sorting of the interleukin 2 receptor beta chain
to late endocytic compartments. Mol Biol Cell 12: 1293–1301.
36. Lefkowitz RJ (1998) G protein-coupled receptors. III. New roles for receptor
kinases and beta-arrestins in receptor signaling and desensitization. J Biol Chem
273: 18677–18680.
37. Lee PS, Wang Y, Dominguez MG, Yeung YG, Murphy MA, et al. (1999) The
Cbl protooncoprotein stimulates CSF-1 receptor multiubiquitination and
endocytosis, and attenuates macrophage proliferation. Embo J 18: 3616–3628.
38. Tartare-Deckert S, Sawka-Verhelle D, Murdaca J, Van Obberghen E (1995)
Evidence for a differential interaction of SHC and the insulin receptor substrate-
1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-
hybrid system. J Biol Chem 270: 23456–23460.
39. Craparo A, O’Neill TJ, Gustafson TA (1995) Non-SH2 domains within insulin
receptor substrate-1 and SHC mediate their phosphotyrosine-dependent
interaction with the NPEY motif of the insulin-like growth factor I receptor.
J Biol Chem 270: 15639–15643.
40. Ashcroft M, Ludwig RL, Woods DB, Copeland TD, Weber HO, et al. (2002)
Phosphorylation of HDM2 by Akt. Oncogene 21: 1955–1962.
41. Mayo LD, Donner DB (2001) A phosphatidylinositol 3-kinase/Akt pathway
promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl
Acad Sci U S A 98: 11598–11603.
42. Zhou BP, Liao Y, Xia W, Spohn B, Lee MH, et al. (2001) Cytoplasmic
localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-
overexpressing cells. Nat Cell Biol 3: 245–252.
43. Rubini M, Hongo A, D’Ambrosio C, Baserga R (1997) The IGF-I receptor in
mitogenesis and transformation of mouse embryo cells: role of receptor number.
Exp Cell Res 230: 284–292.
44. Plas DR, Thompson CB (2003) Akt activation promotes degradation of tuberin
and FOXO3a via the proteasome. J Biol Chem 278: 12361–12366.
45. Colombo MG, Citti L, Basta G, De Caterina R, Biagini A, et al. (2001)
Differential ability of human endothelial cells to internalize and express
exogenous DNA. Cardiovasc Drugs Ther 15: 25–29.
46. Oli MW, Cotlin LF, Shiflett AM, Hajduk SL (2006) Serum resistance-associated
protein blocks lysosomal targeting of trypanosome lytic factor in Trypanosoma
brucei. Eukaryot Cell 5: 132–139.
IGF-1R Ubiquitination
PLoS ONE | www.plosone.org 8 April 2007 | Issue 4 | e340